K. M. Chin and L. J. Rubin, Pulmonary arterial hypertension, J Am Coll Cardiol. 22 avr, vol.51, issue.16, pp.1527-1565, 2008.

A. Vonk-noordegraaf, F. Haddad, K. M. Chin, P. R. Forfia, S. M. Kawut et al., Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology, J Am Coll Cardiol. 24 déc, vol.62, pp.22-33, 1925.

N. Galiè and L. J. Rubin, Introduction: new insights into a challenging disease: A review of the third world symposium on pulmonary arterial hypertension, J Am Coll Cardiol. 16 juin, vol.43, issue.12, p.1, 2004.

B. Sztrymf, R. Souza, L. Bertoletti, X. Jaïs, O. Sitbon et al., Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension, Eur Respir J. juin, vol.35, issue.6, pp.1286-93, 2010.

N. Galiè, M. Humbert, J. Vachiery, S. Gibbs, I. Lang et al., , 2015.

. Esc/ers, Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT), Eur Heart J. 1 janv, vol.37, issue.1, pp.67-119, 2016.

R. Budhiraja, R. M. Tuder, and P. M. Hassoun, Endothelial Dysfunction in Pulmonary Hypertension, Circulation. 20 janv, vol.109, issue.2, pp.159-65, 2004.

S. L. Archer, E. K. Weir, and M. R. Wilkins, The Basic Science of Pulmonary Arterial Hypertension for Clinicians: new concepts and experimental therapies, Circulation. 11 mai, vol.121, issue.18, pp.2045-66, 2010.

K. L. Lannan, R. P. Phipps, and R. J. White, Thrombosis, platelets, microparticles, and PAH: More than clot, Drug Discov Today. août, vol.19, issue.8, pp.1230-1235, 2014.

G. Simonneau, I. M. Robbins, M. Beghetti, R. N. Channick, M. Delcroix et al., Updated clinical classification of pulmonary hypertension, J Am Coll Cardiol. 30 juin, vol.54, issue.1, pp.43-54, 2009.

G. Simonneau, M. A. Gatzoulis, I. Adatia, D. Celermajer, C. Denton et al., Updated clinical classification of pulmonary hypertension, J Am Coll Cardiol. 24 déc, vol.62, pp.34-41, 1925.

S. M. Scharf, M. Iqbal, C. Keller, G. Criner, S. Lee et al., Hemodynamic characterization of patients with severe emphysema, Am J Respir Crit Care Med. 1 août, vol.166, issue.3, pp.314-336, 2002.

M. Oswald-mammosser, E. Weitzenblum, E. Quoix, G. Moser, A. Chaouat et al., Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure, Chest. mai, vol.107, issue.5, pp.1193-1201, 1995.

K. Portillo, Y. Torralba, I. Blanco, F. Burgos, R. Rodriguez-roisin et al., Pulmonary hemodynamic profile in chronic obstructive pulmonary disease, Int J Chron Obstruct Pulmon Dis. 14 juill, vol.10, pp.1313-1333, 2015.

W. Seeger, Y. Adir, J. A. Barberà, H. Champion, J. G. Coghlan et al., Pulmonary hypertension in chronic lung diseases, J Am Coll Cardiol. 24 déc, vol.62, pp.109-116, 1925.

A. Chaouat, A. Bugnet, N. Kadaoui, R. Schott, I. Enache et al., Severe pulmonary hypertension and chronic obstructive pulmonary disease, Am J Respir Crit Care Med. 15 juill, vol.172, issue.2, pp.189-94, 2005.

K. Portillo, Y. Torralba, I. Blanco, F. Burgos, R. Rodriguez-roisin et al., Pulmonary hemodynamic profile in chronic obstructive pulmonary disease, Int J Chron Obstruct Pulmon Dis, vol.10, pp.1313-1333, 2015.

K. Vonbank, R. Ziesche, T. W. Higenbottam, L. Stiebellehner, V. Petkov et al., Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe, COPD. Thorax. 1 avr, vol.58, issue.4, pp.289-93, 2003.

M. J. Brewis, A. C. Church, M. K. Johnson, and A. J. Peacock, Severe pulmonary hypertension in lung disease: phenotypes and response to treatment, Eur Respir J. nov, vol.46, issue.5, pp.1378-89, 2015.

G. Raghu, J. Behr, K. K. Brown, J. J. Egan, S. M. Kawut et al., Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial, Ann Intern Med. 7 mai, vol.158, issue.9, pp.641-650, 2013.

M. M. Hoeper, S. H. Lee, R. Voswinckel, M. Palazzini, X. Jais et al., Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers, J Am Coll Cardiol. 19 déc, vol.48, issue.12, pp.2546-52, 2006.

G. Kovacs, A. Avian, M. Pienn, R. Naeije, and H. Olschewski, Reading pulmonary vascular pressure tracings. How to handle the problems of zero leveling and respiratory swings, Am J Respir Crit Care Med. 1 août, vol.190, issue.3, pp.252-259, 2014.

M. M. Hoeper, R. Maier, J. Tongers, J. Niedermeyer, J. M. Hohlfeld et al., Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension, Am J Respir Crit Care Med. août, vol.160, issue.2, pp.535-576, 1999.

R. Kessler, M. Faller, E. Weitzenblum, A. Chaouat, A. Aykut et al.,

, Natural history » of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease, Am J Respir Crit Care Med. 15 juill, vol.164, issue.2, pp.219-243, 2001.

J. M. Hilde, I. Skjørten, V. Hansteen, M. N. Melsom, J. Hisdal et al., Haemodynamic responses to exercise in patients with COPD, Eur Respir J. mai, vol.41, issue.5, pp.1031-1072, 2013.

B. G. Boerrigter, H. J. Bogaard, P. Trip, H. Groepenhoff, H. Rietema et al., Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension, Chest, vol.142, issue.5, pp.1166-74, 2012.

B. G. Boerrigter, A. B. Waxman, N. Westerhof, A. Vonk-noordegraaf, and D. M. Systrom, Measuring central pulmonary pressures during exercise in COPD: how to cope with respiratory effects, Eur Respir J. mai, vol.43, issue.5, pp.1316-1341, 2014.

. Références,

N. Galiè, M. Humbert, J. Vachiery, S. Gibbs, I. Lang et al., , 2015.

. Esc/ers, Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the

, Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT), Eur Heart J, vol.37, pp.67-119, 2016.

S. M. Scharf, M. Iqbal, C. Keller, G. Criner, S. Lee et al., Hemodynamic characterization of patients with severe emphysema, Am J Respir Crit Care Med, vol.166, pp.314-336, 2002.

G. Thabut, G. Dauriat, J. B. Stern, D. Logeart, A. Lévy et al., Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation, Chest, vol.127, pp.1531-1537, 2005.

A. Chaouat, A. Bugnet, N. Kadaoui, R. Schott, I. Enache et al., Severe pulmonary hypertension and chronic obstructive pulmonary disease, Am J Respir Crit Care Med, vol.172, pp.189-94, 2005.

M. Oswald-mammosser, E. Weitzenblum, E. Quoix, G. Moser, A. Chaouat et al., Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure, Chest, vol.107, pp.1193-1201, 1995.

V. Cottin, L. Pavec, J. Prévot, G. Mal, H. Humbert et al., Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome, Eur Respir J, vol.35, pp.105-116, 2010.
URL : https://hal.archives-ouvertes.fr/hal-01608607

C. J. Lettieri, S. D. Nathan, S. D. Barnett, S. Ahmad, and A. F. Shorr, Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis, Chest, vol.129, pp.746-52, 2006.

A. F. Shorr, J. L. Wainright, C. S. Cors, C. J. Lettieri, and S. D. Nathan, Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant, Eur Respir J, vol.30, pp.715-736, 2007.

E. Weitzenblum, A. Chaouat, and R. Kessler, Pulmonary hypertension in chronic obstructive pulmonary disease, Pneumonol Alergol Pol, vol.81, pp.390-398, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00597163

A. Chaouat, O. Sitbon, M. Mercy, R. Ponçot-mongars, S. Provencher et al., Prognostic value of exercise pulmonary haemodynamics in pulmonary arterial hypertension, Eur Respir J, vol.44, pp.704-717, 2014.

E. Grünig, H. Tiede, E. O. Enyimayew, N. Ehlken, H. Seyfarth et al., Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension, Circulation, vol.128, pp.2005-2020, 2013.

O. A. Spruijt, F. S. De-man, H. Groepenhoff, F. Oosterveer, N. Westerhof et al., The effects of exercise on right ventricular contractility and right ventricular-arterial coupling in pulmonary hypertension, Am J Respir Crit Care Med, vol.191, pp.1050-1057, 2015.

B. G. Boerrigter, H. J. Bogaard, P. Trip, H. Groepenhoff, H. Rietema et al., Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension, Chest, vol.142, pp.1166-74, 2012.

, ATS statement: guidelines for the six-minute walk test, ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories, vol.166, pp.111-118, 2002.

B. G. Boerrigter, A. B. Waxman, N. Westerhof, A. Vonk-noordegraaf, and D. M. Systrom, Measuring central pulmonary pressures during exercise in COPD: how to cope with respiratory effects, Eur Respir J, vol.43, pp.1316-1341, 2014.

C. Casanova, B. R. Celli, P. Barria, A. Casas, C. Cote et al., The 6-min walk distance in healthy subjects: reference standards from seven countries, Eur Respir J, vol.37, pp.150-156, 2011.

L. H. Degani-costa, B. Levarge, S. R. Digumarthy, A. S. Eisman, R. S. Harris et al., Pulmonary vascular response patterns during exercise in interstitial lung disease, Eur Respir J, vol.46, pp.738-787, 2015.

D. Dumitrescu, C. Nagel, G. Kovacs, T. Bollmann, M. Halank et al., Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis, 2017.

A. Stamm, S. Saxer, M. Lichtblau, E. D. Hasler, S. Jordan et al., Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis

, Eur Respir J, vol.48, pp.1658-67, 2016.

J. M. Hilde, I. Skjørten, V. Hansteen, M. N. Melsom, J. Hisdal et al., Haemodynamic responses to exercise in patients with COPD, Eur Respir J, vol.41, pp.1031-1072, 2013.

M. J. Brewis, A. C. Church, M. K. Johnson, and A. J. Peacock, Severe pulmonary hypertension in lung disease: phenotypes and response to treatment, Eur Respir J, vol.46, pp.1378-89, 2015.

J. Hurdman, R. Condliffe, C. A. Elliot, A. Swift, S. Rajaram et al., Pulmonary hypertension in COPD: results from the ASPIRE registry, Eur Respir J, vol.41, pp.1292-301, 2013.

A. Chaouat, O. Sitbon, M. Mercy, R. Ponçot-mongars, S. Provencher et al., Prognostic value of exercise pulmonary haemodynamics in pulmonary arterial hypertension, Eur Respir J, vol.44, pp.704-717, 2014.

E. Grünig, H. Tiede, E. O. Enyimayew, N. Ehlken, H. Seyfarth et al., Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension, Circulation, vol.128, pp.2005-2020, 2013.

O. A. Spruijt, F. S. De-man, H. Groepenhoff, F. Oosterveer, N. Westerhof et al., The effects of exercise on right ventricular contractility and right ventricular-arterial coupling in pulmonary hypertension, Am J Respir Crit Care Med, vol.191, pp.1050-1057, 2015.

R. De and L. A. Thèse-l&apos;hypertension-pulmonaire, Les données fonctionnelles respiratoires ont également été colligées. 3 groupes ont été comparés : HTP du groupe 3 sévère, HTP du groupe 3 non sévère et HTAP. 130 patients ont été inclus entre le 1 er janvier 2005 et le 31 décembre 2015. 20 dans le groupe HTP non sévère, 51 dans le groupe HTP sévère et 59 dans le groupe HTAP. Les patients avec une HTP due à une maladie respiratoire étaient plus âgés (moyennes respectives de 64 et 67 ans pour les groupes HTP non sévère et sévère) que les patients du groupe HTAP (54 ans). Le VEMS et la CVF étaient significativement plus sévères dans le groupe HTP non sévère (VEMS 42% ± 25,9, CVF 68% ± 20,5 et VEMS/CVF 48% ± 21,1), que dans le groupe HTP sévère due à une IRC (VEMS 66% ± 26,6, CVF 82% ± 21,7 et VEMS/CVF 62% ± 16,3). Les valeurs moyennes de distance au TM6 dans les 3 groupes étaient de 308 ± 24 m, 266 ± 14 m et 377 ± 14 m, respectivement dans les groupes HTP non sévère, HTP sévère et HTAP. La pression artérielle pulmonaire moyenne (PAPm) était de 29 mmHg, 40 mmHg et 49 mmHg, HTP) sévère est une complication connue de l'insuffisance respiratoire chronique (IRC). L'HTP sévère liée à l'IRC, définie par une PAPm > 35 mmHg ou une diminution de l'index cardiaque (IC) < 2,5 l/min/m 2 , est beaucoup plus rare. Cette dernière entité présente des caractéristiques fonctionnelles et hémodynamiques plus sévères, se rapprochant de celles de l'hypertension artérielle pulmonaire. Tous les patients atteints d'HTAP et d'HTP du groupe 3 ont été inclus rétrospectivement entre janvier 2005 et décembre, vol.421, p.0, 2001.